Monitor for any definitive clinical trial agreement with DoH Abu Dhabi or a binding collaboration contract — the MoU is non-binding and exploratory. The compassionate-use anecdote is not a substitute for controlled trial data; watch for NEO100-03 pediatric Phase 1 enrollment updates in future filings.
Price Chart
Executive Summary
NeOnc Technologies filed an 8-K reporting three press releases: early clinical improvement in a single pediatric compassionate-use patient treated with NEO100 in Abu Dhabi, a non-binding MoU with the Department of Health – Abu Dhabi to explore research collaboration, and a scheduled appearance on a Fox Business TV segment. These are early-stage, non-financial, non-binding events with no revenue, earnings, or regulatory approval data — the filing is routine disclosure with no material financial impact.
Key Facts
- A 3-year-old boy with an aggressive brain tumor treated under compassionate use with NEO100 is reported to be breathing independently and moving his legs; this is a single-patient observation, not a clinical trial result.
- NeOnc signed a non-binding MoU with the Department of Health – Abu Dhabi to explore scientific exchange, training, and potential clinical research collaboration; no definitive agreement or funding is in place.
- Two children in Abu Dhabi are receiving NEO100 under compassionate use; a third is expected from India.
- NeOnc will be featured on 'Health Uncensored with Dr. Drew' on Fox Business Network on October 25, 2026.
- No financial data, revenue, earnings, guidance, or material agreements were disclosed in this filing.
Financial Impact
No financial figures disclosed in the filing.
Risk Factors
- The MoU is non-binding and may not result in any definitive agreement or clinical trial.
- Single-patient compassionate-use observations do not establish safety or efficacy and are not predictive of future trial results.
- NEO100 remains investigational with no marketing approval from any regulatory authority.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-011446 |
| Document: neonctechnologies_ex99-2.htm | 0001829126-26-011446 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-011446 |
| Document: neonctechnologies_ex99-3.htm | 0001829126-26-011446 |
| Document: 0001829126-26-011446-index-headers.html | 0001829126-26-011446 |
| Document: 0001829126-26-011446-index.html | 0001829126-26-011446 |
| Document: 0001829126-26-011446.txt | 0001829126-26-011446 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.27 | awaiting T+60 | — | $2.82 (−13.76%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $2.82 (+4.44%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $2.82 (−15.32%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $2.82 (−17.30%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $2.82 (−5.69%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $2.82 (+22.95%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $2.82 (+22.95%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $2.82 (−39.68%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $2.82 (−49.01%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $2.82 (−18.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers